Literature DB >> 31703386

Imaging Features of Multiple Myeloma Extramedullary Lesions in the Liver with 18F-FDG PET/CT, Contrast-Enhanced CT and MRI.

Dimitris Papamichail1, Robert Hog1, Hartmut Goldschmidt2, Antonia Dimitrakopoulou-Strauss1.   

Abstract

Ηepatic involvement in multiple myeloma is not common; nevertheless, it is associated with poorer outcome. Heterogeneous features have been described in few published reports so far. We present the imaging findings of PET/CT in comparison to those of MRI for two multiple myeloma (MM) patients, one with a liver lesion suspicious for myeloma metastasis on PET and one with multiple liver lesions suspicious for myeloma metastases on MRΙ. The subsequent ultrasound-guided needle biopsies confirmed the extramedullary spread of the disease in both patients. The first case exhibited a match in both functional imaging modalities (PET and MRI) but a mismatch of intense metabolic activity on 18F-fluorodeoxyglucose (18F-FDG) PET/CT and iso-attenuating liver parenchyma on contrast-enhanced CT. The second case showed a mismatch of signal elevation persistence on diffusion-weighted imaging (DWI) and physiologic 18F-FDG distribution in the liver parenchyma. These cases present different imaging features in MM lesions of the liver using PET/CT and MRI, reflecting the high disease heterogeneity in patients with MM and demonstrating that the use of both PET/CT and MRI may offer complementary information.

Entities:  

Keywords:  18F-FDG PET/CT; MRI; contrast-enhanced CT; extramedullary; multiple myeloma

Year:  2019        PMID: 31703386      PMCID: PMC6963877          DOI: 10.3390/diagnostics9040179

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


Newly diagnosed patient with multiple myeloma (MM, Typ IgA Kappa, Stage IIIA according to the Durie–Salmon staging system, ISS III), anemia and hepatosplenomegaly underwent an 18F-FDG PET/CT and a routine whole-body MRI investigation, as it is standard for all MM patients. The transaxial fused PET/CT image (a) shows a circumscribed lesion in the IVb segment of the liver (red arrow) with an SUVmax of 10.1, a functional volume of approx. 90 ml and a hypometabolic center. At the same level, a cystic liver lesion of 9 cm in diameter is delineated (without FDG-uptake). The FDG-avid lesion is not distinguishable in the low-dose CT (b). The contrast-enhanced diagnostic CT (c) shows a contrast uptake in the arterial phase nearly similar to the liver parenchyma, and a hypodense core demarks itself as in the PET/CT-image. Diffusion-weighted (DW d,e) MRI demonstrates an inhomogeneous abnormal diffusion restriction in the same area (green arrows), which can be clearly distinguished, showing an intermediate T1-signal intensity and a hyperintense core (yellow arrow) in the contrast-enhanced MRI (f). A biopsy of the lesion under sonographic control indicated plasma cell neoplasia. A diagnostic ultrasound of the liver was not performed before (no pre-described MM hepatic disease). The presence of extramedullary lesions at any time during the course of MM indicates a poor prognosis [1], and these patients may need to follow additional treatment strategies [2,3]. A patient with MM (Typ IgG lambda, Stage IA according to the Durie–Salmon staging system, ISS I) underwent an 18F-FDG PET/CT and a routine whole-body MRI investigation after radiation therapy of an extensive plasma cell infiltration in the sternum and three courses of induction therapy. No signs of further focal lesions were illustrated in previous CT and MRI investigations. A contrast-enhanced CT-scan was not performed in this case. The subsequent 18F-FDG PET/CT (a,b) did not demonstrate any focal lesion in the liver. A small lesion of 8 mm was delineated in Segment IVb, with an abnormal diffusion restriction in diffusion-weighted (DW, c) MRI (red arrow). The same lesion could not be distinguished in the T1-VIBE or T2-weighted sequences (d). A diagnostic ultrasound of the liver was not performed before (no pre-described hepatic disease), while the biopsy of the lesion under sonographic control indicated plasma cell neoplasia. Chen et al. reported a sensitivity of PET/CT nearly equivalent to that of MRI for the detection of extramedullary lesions; however, they added that in some areas, the use of both techniques could offer complementary information [4]. It must be noted that small lesions with a subcentimeter size may not be detectable on 18F-FDG PET, due to volume averaging in relation to the limited spatial resolution of the PET scanner [5]. This case report confirms the presumption of Chen et al. and reflects the high disease heterogeneity in patients with MM.
  5 in total

1.  Comparison of Whole-Body DWI and 18F-FDG PET/CT for Detecting Intramedullary and Extramedullary Lesions in Multiple Myeloma.

Authors:  Jianpu Chen; Chongjiao Li; Yueli Tian; Qing Xiao; Ming Deng; Hao Hu; Bing Wen; Yong He
Journal:  AJR Am J Roentgenol       Date:  2019-06-05       Impact factor: 3.959

2.  Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.

Authors:  Saad Z Usmani; Christoph Heuck; Alan Mitchell; Jackie Szymonifka; Bijay Nair; Antje Hoering; Yazan Alsayed; Sarah Waheed; Sajjad Haider; Alejandro Restrepo; Frits Van Rhee; John Crowley; Bart Barlogie
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

3.  Value of FDG PET in the assessment of patients with multiple myeloma.

Authors:  Miriam A Bredella; Lynne Steinbach; Gary Caputo; George Segall; Randall Hawkins
Journal:  AJR Am J Roentgenol       Date:  2005-04       Impact factor: 3.959

4.  Extramedullary multiple myeloma escapes the effect of thalidomide.

Authors:  Laura Rosiñol; Ma Teresa Cibeira; Joan Bladé; Jordi Esteve; Marta Aymerich; María Rozman; Marta Segarra; Maria C Cid; Xavier Filella; Emili Montserrat
Journal:  Haematologica       Date:  2004-07       Impact factor: 9.941

5.  Bortezomib: an effective agent in extramedullary disease in multiple myeloma.

Authors:  Rosiñol Laura; Maria Teresa Cibeira; Carla Uriburu; Sebastián Yantorno; Olga Salamero; Joan Bladé; Emili Montserrat
Journal:  Eur J Haematol       Date:  2006-03-09       Impact factor: 2.997

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.